196 related articles for article (PubMed ID: 11236066)
1. Viral vectors for gene therapy in Parkinson's disease.
Latchman DS; Coffin RS
Rev Neurosci; 2001; 12(1):69-78. PubMed ID: 11236066
[TBL] [Abstract][Full Text] [Related]
2. Viral vectors in the treatment of Parkinson's disease.
Latchman DS; Coffin RS
Mov Disord; 2000 Jan; 15(1):9-17. PubMed ID: 10634236
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.
Sun M; Kong L; Wang X; Holmes C; Gao Q; Zhang GR; Pfeilschifter J; Goldstein DS; Geller AI
Hum Gene Ther; 2004 Dec; 15(12):1177-96. PubMed ID: 15684695
[TBL] [Abstract][Full Text] [Related]
4. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.
Kelly MJ; O'Keeffe GW; Sullivan AM
Expert Rev Mol Med; 2015 May; 17():e8. PubMed ID: 25997719
[TBL] [Abstract][Full Text] [Related]
5. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
Eslamboli A; Georgievska B; Ridley RM; Baker HF; Muzyczka N; Burger C; Mandel RJ; Annett L; Kirik D
J Neurosci; 2005 Jan; 25(4):769-77. PubMed ID: 15673656
[TBL] [Abstract][Full Text] [Related]
6. Scientific rationale for the development of gene therapy strategies for Parkinson's disease.
Björklund T; Kirik D
Biochim Biophys Acta; 2009 Jul; 1792(7):703-13. PubMed ID: 19254760
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for Parkinson's disease.
Horellou P; Mallet J
Mol Neurobiol; 1997 Oct; 15(2):241-56. PubMed ID: 9396012
[TBL] [Abstract][Full Text] [Related]
8. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
9. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors.
Ozawa K; Fan DS; Shen Y; Muramatsu S; Fujimoto K; Ikeguchi K; Ogawa M; Urabe M; Kume A; Nakano I
J Neural Transm Suppl; 2000; (58):181-91. PubMed ID: 11128607
[TBL] [Abstract][Full Text] [Related]
11. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
[TBL] [Abstract][Full Text] [Related]
12. Biomedicine. Combating Parkinson's disease--step three.
Olson L
Science; 2000 Oct; 290(5492):721-4. PubMed ID: 11184202
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector.
Azzouz M; Ralph S; Wong LF; Day D; Askham Z; Barber RD; Mitrophanous KA; Kingsman SM; Mazarakis ND
Neuroreport; 2004 Apr; 15(6):985-90. PubMed ID: 15076720
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.
Muramatsu S; Tsukada H; Nakano I; Ozawa K
Expert Opin Biol Ther; 2005 May; 5(5):663-71. PubMed ID: 15934841
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.
McGrath J; Lintz E; Hoffer BJ; Gerhardt GA; Quintero EM; Granholm AC
Cell Transplant; 2002; 11(3):215-27. PubMed ID: 12075987
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline-regulated co-expression of GDNF and TH in PC12 cells.
Wang JJ; Zhang T; Niu DB; Wang K; Li KR; Xue B; Wang XM
Neurosci Lett; 2006 Jun; 401(1-2):142-5. PubMed ID: 16584838
[TBL] [Abstract][Full Text] [Related]
17. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease.
Bowers WJ; Howard DF; Federoff HJ
Exp Neurol; 1997 Mar; 144(1):58-68. PubMed ID: 9126153
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF.
McBride JL; Kordower JH
Prog Brain Res; 2002; 138():421-32. PubMed ID: 12432782
[No Abstract] [Full Text] [Related]
20. Gene therapy for Parkinson's disease: progress and challenges.
Chen Q; He Y; Yang K
Curr Gene Ther; 2005 Feb; 5(1):71-80. PubMed ID: 15638712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
